Genentech’s lawsuit against Amgen has come to a quick (although perhaps temporary) end, with the Court dismissing Genentech’s complaint...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
Legal
-
-
Inter partes review (“IPR”) is one of several post-grant procedures created by the Leahy Smith America Invents Act (“AIA”). An...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Celltrion, Inc. (“Celltrion”) filed a petition with the Patent Trial and Appeal Board (“PTAB”) on August 15, 2016 for inter partes...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Celltrion, Inc. (“Celltrion”) filed a new petition with the Patent Trial and Appeal Board (“PTAB”) on February 21, 2017 for inter...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On February 15, 2017, Genentech filed litigation accusing Amgen of violating the Biologics Price Competition and Innovation Act...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Coherus Biosciences, Inc. (“Coherus”) has filed four petitions with the Patent Trial and Appeal Board (“PTAB”) for inter partes...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Hospira, Inc. (“Hospira”) filed two additional new petitions with the Patent Trial and Appeal Board (“PTAB”) on January 30, 2017...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
The Supreme Court has agreed to hear its first biosimilar case interpreting two provisions of the Biologics Price Competition and...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Hospira, Inc. (“Hospira”) filed three petitions with the Patent Trial and Appeal Board (“PTAB”) on January 20, 2017 for inter...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]